GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Common Stock

I-MAB (IMAB) Common Stock : $0.02 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB Common Stock?

I-MAB's quarterly common stock stayed the same from Dec. 2022 ($0.02 Mil) to Jun. 2023 ($0.02 Mil) and stayed the same from Jun. 2023 ($0.02 Mil) to Dec. 2023 ($0.02 Mil).

I-MAB's annual common stock declined from Dec. 2021 ($0.02 Mil) to Dec. 2022 ($0.02 Mil) but then stayed the same from Dec. 2022 ($0.02 Mil) to Dec. 2023 ($0.02 Mil).

I-MAB Common Stock Historical Data

The historical data trend for I-MAB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Common Stock Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial - 0.02 0.02 0.02 0.02

I-MAB Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02

I-MAB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

I-MAB (IMAB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Common Stock
Comparable Companies
PLX GLSI CDXS CYT SEER PROK MLEC AADI ABSI GOSS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
0VY:Germany
Address
555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124
Website
https://www.i-mabbiopharma.com
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.